Emerging Leader Lectureships
The purpose of the Emerging Leader Lectureships is to recognise young scientists and clinical scientists within the region and encourage them as the ‘rising stars’ of the future.
- Nominees must be forty-five (45) years of age or younger at the time the nomination is submitted.
- Provide their CV and title of their lecture and abstract.
- Demonstrate excellence in research, and that they are an outstanding contributor in their age group.
- In principal be established in their own right i.e. Associate Professor.
- Must submit a review article for publication in the journal.
- Provide their submission via their local society.
- Be received by 31 July each year.
- Maximum of one (1) nominee per country.
- A total of two (2) lectureships per meeting are awarded.
- The Trustees of the JGH Foundation will make the final decision on the selection of the two (2) lecturers.
- Return economy class airfare between home city and the venue for APDW.
- Accommodation in a single room at one of the conference hotels to cover the night before speaking engagement commences until and including the night after participation (maximum 4 nights).
- Honorarium of US$1,000 for submission of manuscript for publication in JGH at the time of the meeting.
Each lecturer is required to submit a manuscript for publication in the Journal of Gastroenterology and Hepatology (JGH) that covers the content of their lecture. The manuscript should be structured as a review article between 2,500-3,000 words. For information on JGH style guidelines please see the Wiley-Blackwell House Style Guide
Past Award Recipients
|2017||Grace Wong||Hong Kong||Non-invasive assessments for liver fibrosis - the crystal ball we long for|
|Norihisa Ishimura||Shimane||Eosinophilic esophagitis and proton pump inhibitor-responsive eosinophilia: distinct disease entities?|
|2016||Philip Chiu||Hong Kong||Innovation and Advances in Endoscopic Surgery|
|Ming-Lung Yu||Kaohsiung||Treatment of chronic HCV infection: From Response-guided therapy to Resource-guided therapy in the transition era from Interferon-containing to Interferon-free regimens|
|2015||Chun-Ying Wu||Taichung||A Roadmap to Prevent Digestive Cancers: From molecular studies, clinical researches, big data analyses, to personal risk prediction and biochips development|
|Young-Suk Lim||Seoul||Achieving the Goal of Hepatitis B Treatment|
|2014||Siew Chien Ng||Hong Kong||Inflammatory bowel disease in Asia: emergence of a "Western Disease"|
|Yock Young Dan||Singapore||Liver's Holy Grail? - The Somatic Liver Stem Cell and its Therapeutic Applications|
|2013||Katsunori Iijima||Sendai||Involvement of luminal nitric oxide in the pathogenesis of gastro-esophageal reflux disease spectrum|
|Chun-Jen Liu||Taipei||Dual HCV and HBV Infection: Resolved and unresolved issues|
|2012||Vincent Wai Sung, Wong||Hong Kong||Nonalcoholic Fatty Liver Disease in Asia - A Story of Growth|
|Jae Hee Cheon||Seoul||Genetics and epigenetics in the pathogenesis of inflammatory bowel diseases|
|2011||Manoj Sharma||New Delhi||Chronic hepatitis B infection and normal ALT: treat or not to treat?|
|Ping-I Hsu||Kaohsiung||A new look at antiplatelet agent-related peptic ulcer: An update of prevention and treatment|
|2010||Henry Lik-Yuen Chan||Hong Kong||The decoding of HBV genomics by a clinician|
|Khek-Yu Ho||Singapore||From GERD to Barrett's oesophagus: Is the pattern in Asia mirroring that in the West?|
|2009||Bor-Shyang Sheu||Taipei||Helicobacter Pylori Colonization of the Human Gastric Epithelium: the First Step of Bug & Novel Target for Us.|
|Rong-Nan Chien||Taipei||On Treatment Monitoring of Chronic Hepatitis B Virus Infection: an Asian Pacific Perspective|
|2008||Ming-Shiang Wu||Taipei||Proteomic identifications of biomarkers related to Helicobacter pylori-associated gastroduodenal diseases: challenges and opportunity|
|Che-Yuen Justin Wu||Hong Kong||Gastroesophageal reflux disease:An Asian perspective|
|2007||Kai-Chun Wu||Xian||Molecular basis of therapeutic approaches to gastric cancer|
|Isao Sakaida||Japan||Autologous bone marrow cell infusion ( ABMI ) therapy for liver cirrhosis|